Azer-cel Granted FDA Fast Track Designation for CLL and MZL
Filed with ASX · · 3 pages · English
Summary by 6ix AI
This designation is intended to expedite the development and review process for therapies addressing serious conditions with unmet medical needs. Clinical data shows significant response rates for azer-cel in patients who have not previously received cellular therapy, highlighting its potential as a treatment option.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- First Patient in BTKi Combination Cohort of azer-cel study
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Prospectus
- $20M placement and SPP, convertible notes amended
Later from Imugene
- First Complete Response in Concurrent BTKi azer-cel Cohort
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- $11.1 Million Placement Completed to Advance azer-cel
- Third response in concurrent BTKi Cohort of azer-cel Trial
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene